Clinical trials
Acute Leukemia clinical trials
Below are recruiting acute leukemia clinical trials, each written for real people, not researchers. We’re tracking 939 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05947344RecruitingPhase 1
Testing STI-8591 for advanced acute myeloid leukemia
This early-stage study tests STI-8591 in people with advanced acute myeloid leukemia (AML) or certain related blood cancers. It mainly aims to find a safe dose and see whether the treatment can work for patients whose disease did not respond to standard care or who cannot get it.
Hangzhou, ZhejiangAges 18 years+ - NCT05963971Recruiting
Bilingual online program to prevent weight gain in childhood leukemia
This trial tests a bilingual, online program to help children and teens who have ALL (a type of leukemia) stay at a healthy weight during the maintenance phase of treatment. It may help lower the chance of gaining too much weight while on chemotherapy.
New York, New YorkAges 5–21 - NCT05986240RecruitingPhase 1
Danvatirsen with or without venetoclax for advanced MDS or AML
This trial tests a new drug called danvatirsen, first alone and then combined with venetoclax, for people with advanced myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) that has come back or not responded to treatment. It aims to see if this approach can help when other options have stopped working.
The Bronx, New YorkAges 18 years+ - NCT05991908RecruitingPhase 3
Comparing chemotherapy regimens before stem cell transplant for blood cancers
This trial is testing two different chemotherapy regimens (with one or two alkylating agents) before a stem cell transplant for people with acute myeloid leukemia or myelodysplastic syndrome. The goal is to find which conditioning treatment is safer and more effective.
Fuzhou, FujianAges 16–55 - NCT05995041RecruitingPhase 1
Universal CAR-T cells for acute myeloid leukemia
This trial tests a type of immunotherapy called CAR-T cells that are made to target leukemia cells. The cells are designed to attack AML by recognizing several proteins on the cancer cells, and may be an option for patients who have not responded well to other treatments.
Shenzhen, GuangdongAges 6 months–75 years - NCT06027853RecruitingPhase 1
NK cell therapy for relapsed or refractory AML patients
This trial tests a natural killer (NK) cell therapy that targets a protein called CLL1 on leukemia cells. It aims to help people whose acute myeloid leukemia (AML) has come back or not responded to other treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06046313RecruitingPhase 2
Low-dose decitabine plus venetoclax for older AML/MDS
This trial tests a combination of two drugs (decitabine and venetoclax) at a very low, extended dose for people aged 60 or older who have been newly diagnosed with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to see if this gentler approach is effective and well-tolerated.
Hangzhou, ZhejiangAges 60 years+ - NCT06049667RecruitingPhase 1
Study of NTQ2494 tablets for advanced blood cancer
This trial tests an oral medication (NTQ2494) for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. It aims to see if the drug is safe and effective.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06051409RecruitingPhase 3
Olverembatinib for newly diagnosed Ph+ ALL
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
Birmingham, AlabamaAges 18 years+ - NCT06060782RecruitingPhase 1
Chemo combo for high-risk blood cancer transplant patients
This trial tests a combination of drugs (thiotepa, cyclophosphamide, clarithromycin, and cytarabine) before a stem cell transplant. It is for people with certain types of blood cancer who have responded well to earlier treatment.
Zhuhai, GuangdongAges 18–65 - NCT06074666Recruiting
Parent training to boost medication adherence in pediatric leukemia
This study tests a new parenting program to help improve how well children with leukemia take their oral medications at home. The program focuses on building helpful skills for giving daily medicine.
Buffalo, New YorkAges 3–9 - NCT06080191RecruitingPhase 1
Donor CAR T cells for pediatric B-ALL relapse
This trial uses a one-time infusion of specially grown immune cells (CAR T cells) from a healthy donor to attack leukemia that has come back or not responded to prior treatments. It is for children and young adults with B-cell acute lymphoblastic leukemia that still shows the CD19 marker.
Rome, ItalyAges 1–35 - NCT06129734RecruitingPhase 1/Phase 2
Decitabine and venetoclax after stem cell transplant to prevent relapse
This study tests whether giving two drugs, decitabine and venetoclax, after a stem cell transplant can help keep your leukemia or MDS from coming back. It is for people whose disease is at high risk for relapse.
Cleveland, OhioAges 18 years+ - NCT06191263RecruitingPhase 2
RVU120 plus venetoclax for relapsed AML
This trial tests a new drug, RVU120, combined with venetoclax for people with AML that has come back or not responded to treatment. It may be an option if you've already tried venetoclax with another drug and it didn't work.
GrenobleAges 18 years+ - NCT06199557RecruitingPhase 1/Phase 2
Gentle drug combo for AML or high-risk MDS
This trial tests a combination of two oral drugs (hydroxyurea and valproic acid, or 6-mercaptopurine and valproic acid) for people with AML or high-risk MDS who are too frail for standard chemotherapy. The goal is to see if this gentler treatment can help control the disease.
Bergen, BergenAges 18 years+ - NCT06220162RecruitingPhase 2
VAC Regimen for AML Not Responding to VA
This trial tests a new drug combination (VAC) for people with acute myeloid leukemia (AML) who did not improve after standard VA treatment. It is for those who cannot have strong chemotherapy due to age or health problems.
Suzhou, JiangsuAges 18–80 - NCT06220487RecruitingPhase 2
New drug combo for Ph+ ALL without transplant
This trial tests a combination of three drugs—olverembatinib, a bispecific T-cell engager, and chidamide—for adults newly diagnosed with Ph+ ALL who cannot have a stem cell transplant. The goal is to see if this treatment works well without needing intensive chemotherapy.
Guangzhou, GuangdongAges 18 years+ - NCT06221683RecruitingPhase 2
Personalized induction therapy for children with AML based on genetics
This trial tests different induction therapy options based on the specific genetic subtype of a child’s AML and how the leukemia responds early on. The goal is to personalize treatment to improve outcomes and reduce side effects.
Hefei, AnhuiAges Up to 18 years - NCT06227026RecruitingPhase 1
CAR-T cell therapy for blood cancers that came back
This trial tests a type of immunotherapy called CAR-T cells, which are your own immune cells modified to attack cancer. It is for adults with certain blood cancers (like lymphoma or leukemia) that have not responded to at least two prior treatments.
Salt Lake City, UtahAges 18 years+ - NCT06232694Recruiting
Combination therapy for newly diagnosed AML
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
Nanjing, JiangsuAges 18–60 - NCT06233526Recruiting
Personalized treatment for children with relapsed or resistant AML
This trial offers a personalized treatment plan for children with hard-to-treat or relapsed acute myeloid leukemia (AML). The plan is based on the unique genetic makeup of the child's cancer and lab tests that find the most effective drugs.
Hangzhou, ZhejiangAges Up to 18 years - NCT06256627Recruiting
Maintenance treatment of 'ITIVA' for AML in remission
This trial tests a maintenance treatment called 'ITIVA' for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy and consolidation therapy. The goal is to see if this treatment helps keep the leukemia from coming back.
Zhengzhou, HenanAges 14 years+ - NCT06284486RecruitingPhase 1/Phase 2
Venetoclax and revumenib for AML with residual disease
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
Baltimore, MarylandAges 12 years+ - NCT06291428Recruiting
Comparing light-based test to standard test for leukemia detection
This study compares a new technique using light to detect leftover leukemia cells (Raman spectroscopy) with the standard method (flow cytometry) in people with acute lymphoblastic leukemia (ALL).
León, GuanajuatoAges 2–70
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute leukemia?
- Yes. Clin2 currently lists 939 recruiting acute leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.